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Abstract The neuropeptide galanin mediates a diverse array of
physiological functions through activation of specific receptors.
Roles of the three recently cloned galanin receptors (GalRs) in
rat intestinal contraction and food intake were examined using
GalR-selective ligands and the results were compared with the
pharmacological profiles of defined GalRs. The action profile of
these ligands in jejunal contraction resembled only that of GalR2
and only a high level of GalR2 mRNA was detected in the tissue,
supporting GalR2 as the receptor mediating jejunal contraction.
The action profile for food intake in rats excluded GalR2, GalR3
and the putative pituitary galanin receptor as the ‘feeding
receptor’, suggesting that either GalR1 or an unidentified GalR
is responsible for mediating this function.
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1. Introduction
Galanin is a neuropeptide with 29^30 amino acids originally
isolated from porcine small intestine [1]. Galanin contains an
amino acid sequence unique to any known family of biolog-
ically active peptides. It is widely distributed in the central and
peripheral nervous systems and is expressed abundantly in
various regions of the brain. Numerous studies have revealed
roles of galanin in modulation of functions in the gastrointes-
tinal system, including motility of the digestive system [1^6],
and in inhibition of release of gastrin, somatostatin, insulin
and gastric acid [7^10]. Several functions associated with the
central nervous system were subsequently shown to be medi-
ated by galanin, including neurotransmitter and hormone re-
lease, spinal re£exes and nociception [11^15]. Centrally ad-
ministered galanin potently stimulates food intake in
animals [16]. The actions of galanin are thought to be medi-
ated through speci¢c galanin receptors. Pharmacological stud-
ies using galanin fragments and chimerical galanin peptides
have indicated the existence of more than one galanin receptor
in di¡erent tissues and cell lines, and have revealed pharma-
cological di¡erences between the brain and gut galanin recep-
tors [17,18].
Recent molecular cloning of galanin receptor subtypes has
provided further understanding of the molecular and pharma-
cological characteristics of galanin receptors. The ¢rst galanin
receptor (GalR1) has been cloned from several species [19^25],
followed by cloning of two more subtypes of galanin receptor
(GalR2 and GalR3) using homology- and function-based ap-
proaches [26^31]. All three receptor subtypes consist of seven
putative transmembrane domains and belong to the G-protein
coupled receptor (GPCR) superfamily. These receptors are
distinguished by their pharmacological pro¢les in membrane
binding assays and by their tissue distributions. Galanin-
(2^29), which lacks Gly1 of galanin, retains high a⁄nity for
GalR2 and GalR3 but possesses reduced a⁄nity for GalR1,
whereas galanin(1^16) displays low a⁄nity for GalR3 and
high a⁄nity for GalR1 and GalR2 [28,30]. [D-Trp2]-Gala-
nin(1^29) also has high a⁄nity for rat GalR2 but low a⁄nity
for rat GalR1 [29]. The expression of GalR1 appears to be
restricted to the central nervous system, only detectable in the
brain and spinal cord [19,23,32]. In contrast, the expression of
GalR2 is more widespread and can be readily detected in both
central and peripheral tissues [26^29]. Unlike GalR1 and
GalR2, the expression of GalR3 is more restricted to periph-
eral tissues [30]. These results suggest a possibility that di¡er-
ent galanin receptor subtypes mediate separate central and
peripheral functions of galanin. However, despite the cloning
of three galanin receptors, the roles of the cloned GalRs have
not been determined. In this report, we describe studies exam-
ining the roles of the GalR1, GalR2 and GalR3 galanin re-
ceptors in modulation of small intestine contraction and gal-
anin-stimulated food intake and the results reveal that the
small intestinal contraction is mediated by GalR2 whereas
the feeding behavior is not regulated by GalR2/GalR3 activa-
tion.
2. Materials and methods
2.1. Materials
[125I]Porcine-galanin (2200 Ci/mmol) and K-[32P]dATP (5000 Ci/
mmol) were purchased from DuPont-NEN (Boston, MA). Rat gala-
nin and rat galanin(1^16) were purchased from Peninsula Laborato-
ries (Belmont, CA). Rat galanin(2^29) and rat galanin(3^29) were
synthesized by Bio-synthesis, Inc. (Lewisville, TX).
2.2. Rat jejunal contraction
Male Sprague-Dawley rats (250^300 g, Charles River, Kingston,
NY) were killed by carbon dioxide inhalation. The jejunal segment
was removed quickly from each animal, and dissected free of vascular
and connective tissues. After washing out the luminal contents, the
jejunum was cut into 15 mm segments and suspended longitudinally in
20 ml organ chambers containing Krebs solution. The Krebs compo-
sition was (mM) NaCl 118, CaCl2 2.55, KCl 4.7, MgSO4 1.2,
KH2PO4 1.2, NaHCO3 24.9, glucose 11.1. The organ chamber was
kept at 37‡C and continuously gassed with 95% O2/5% CO2 to main-
tain the pH at 7.4. Tension changes were measured with a Grass
force-displacement transducer (model FT03) and recorded on a Gould
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(TA4000) recorder. The optimal resting tension, determined by length-
tension relationship with repeated KCl (40 mM) challenge, was 0.5 g.
After equilibration for 60 min at optimal tension, the tissues were
challenged with acetylcholine (ACh) (5 WM). Tissues were washed
several times with Krebs solution and equilibrated for another 45
min. Each jejunal segment was tested with a single concentration of
a galanin analog. The contractile response was expressed as percent-
age of the ACh (5 WM) response. EC50 was calculated as log concen-
tration causing a half-maximal e¡ect of each galanin analog. Data are
expressed as mean þ S.E.M.
2.3. Northern blot analysis
Jejuna from ¢ve rats were removed and transferred immediately to
100 ml of Tri-reagent solution (Molecular Research Center, Cincin-
nati, OH). 1 mg of the total RNA (2.8^3.7 mg) was used for poly(A)
RNA isolation using an oligo(dT) a⁄nity protocol (Fast Track, In-
vitrogen). 5 Wg of the poly(A) RNA was loaded on a 1% denaturing
agarose gel containing 2.2 M formamide. The gel was electrophoresed
at 5 V/cm for approximately 2 h. The RNA was then transferred to a
positively charged Nylon membrane (BrightStar-plus, Ambion, Aus-
tin, TX) by the capillary transfer method [44]. After UV-cross linking,
the blot was hybridized for 15 h at 55‡C in an ExpressHyb solution
(Clontech) using 32P-labeled rat GalR1 (full length cDNA cut with
restriction enzymes HindIII and XbaI from plasmid pcDNA3-rGalR1
and gel puri¢ed), rat GalR2 cDNA (near full length of cDNA (1.3 kb
insert) cut with restriction enzymes HindIII and XbaI from clone
pcDNA3-B45-16-11 [27] and gel puri¢ed), or a GalR3 0.7 kb cDNA
[30] as a probe. After hybridization, the blot was washed with solution
I (2USSC, 0.05% SDS) for 30 min at room temperature then with
wash solution II (0.1USSC, 0.1%SDS) for 30 min at room temper-
ature, 1 h at 48‡C, and 1 h at 55‡C. The blot was then wrapped with
Saran Wrap and exposed to Kodak BioMax ¢lms for 5 h at 380‡C.
The same blot was stripped and similarly hybridized with 32P-labeled
actin cDNA to ensure loading of poly(A) mRNA from the tissues
onto the blot.
2.4. Feeding behavior
Male Sprague-Dawley rats (Charles River) were chronically im-
planted with a single 22G stainless steel guide cannula (Plastics
One, Roanoke, VA) in the lateral ventricle of the brain under keta-
mine:xylazine (100:10 mg/kg i.p.) anesthesia with the following coor-
dinates: 31.0 mm relative to bregma, 1.5 mm lateral of midline, and
3.6 mm below the surface of the skull. The cannula was secured on
the surface of the skull with jeweler’s screws and dental cement, and a
28 gauge wire was inserted into the cannula to maintain patency.
Animals were allowed to recover for 2 weeks, and then acclimated
to consume a milk-mash diet (500 g powdered #5001 rat chow, 400 g
sugar, and 12 oz of condensed milk) for 3 days prior to study. Sterile
saline or galanin(1^29, 1^16, 2^29, or 3^29) in saline was infused i.c.v.
in a total volume of 5 Wl over the course of 1 min via a 28G internal
cannula 4.6 mm below the surface of the skull (Plastics One) attached
to a BAS Bee Syringe Pump (Bioanalytical Systems, West Lafayette,
IN). The infusion cannula was left in place for an additional minute
following the infusion.
Forty-two i.c.v. cannulated Sprague-Dawley rats were divided into
groups of six and administered saline vehicle or galanin(1^29) (1 nmol,
3 nmol, 10 nmol), galanin(1^16), galanin(2^29), or galanin(3^29)
(3 nmol, 10 nmol, 30 nmol) i.c.v. in a crossover design. The animals
were allowed a 48 h washout period between treatments. Food con-
sumption (milk-mash diet) was monitored at 1 h post-dosing, which
was 3 h into the light cycle in the satiated rats. All studies were
conducted in an AAALAC accredited facility following protocols
approved by the Schering-Plough Research Institute’s Animal Care
and Use Committee. The procedures were performed in accordance
with the principles and guidelines established by the NIH for the care
and use of laboratory animals.
2.5. Radioligand binding assay
Chinese hamster ovary (CHO) cell lines expressing rat GalR1 and
rat GalR2 were obtained as previously described [33,34]. Binding of
[125I]porcine galanin to intact CHO cells expressing rat GalR1 or rat
GalR2 was performed in a bu¡er containing PBS (without Ca2/
Mg2), 0.1% bovine serum albumin (w/v), 0.1% bacitracin, 2 Wg/ml
leupeptin, 0.1 mM phenylmethylsulfonyl £uoride (PMSF) and 10 mM
MgCl2. Peptide competition studies were performed in 200 Wl of the
binding bu¡er containing 5U105 cells and 0.3 nM [125I]porcine gal-
anin. After 1 h incubations at room temperature, the assays were
terminated by rapid vacuum ¢ltration through 0.3% polyethylenei-
mine-pretreated Multiscreen FB Filter Plates (cat# MAFB NOB50,
Millipore, Bedford, MA). The ¢lters were then washed three times
with 100 Wl of phosphate bu¡ered saline (pH 7.4) and counted with
a TopCount counter (Hewlett Packard). All data were analyzed using
non-linear regression software (Prism, GraphPad, San Diego, CA)
and the Ki calculated according to the method of Cheng and Pruso¡
[35].
3. Results
3.1. E¡ects of galanin analogs on contractility of jejunal
longitudinal muscle
We ¢rst tested the e¡ects of galanin and its analogs in a
bioassay of jejunal contraction, a tissue in which galanin was
originally discovered [1]. Rat galanin(1^29) elicited a concen-
tration-dependent contraction of rat jejunal longitudinal
muscle over the dose range 10 nM to 10 WM (EC50 = 76 þ 26
nM, Fig. 1). Galanin(2^29) also stimulated the contraction
with a potency (EC50 = 269 þ 57 nM) 3-fold less than that of
galanin(1^29) (Fig. 1). Galanin(1^16), a ligand with low a⁄n-
ity for GalR3, produced an EC50 value similar to that of
galanin(2^29) (370 þ 195 nM, Fig. 1), indicating that the ac-
tion is mediated by a receptor with high a⁄nity for galanin(1^
29), galanin(1^16) and galanin(2^29). In contrast, elimination
of Trp at position 2 of rat galanin resulted in an inactive
peptide (galanin(3^29)), which did not induce any contraction
in rat jejunal muscle (Fig. 1). The maximum e¡ects of the
contraction for all the three active galanin peptides were com-
parable, ranging from 50 to 60% of that elicited by ACh at
5 WM (Fig. 1).
3.2. Expression of the galanin receptor subtypes in rat jejunum
Since the levels of expression of rat GalR2 and GalR3
mRNA in jejunum have not been reported, we measured the
mRNA levels of the rat galanin receptor subtypes in rat jeju-
num by Northern blot analysis. Poly(A) RNA was isolated
from rat jejunum, separated on an agarose gel, blotted onto
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Fig. 1. Concentration-response curves showing the contractile e¡ects
of galanin(1^29) and galanin fragments on longitudinal smooth
muscle of rat jejunum. The contractile responses are expressed as a
percentage of the contraction induced by ACh (5 WM). Each value
is the mean of 5^8 experiments. Vertical bars represent the standard
error of means.
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Nylon membranes and hybridized with 32P-labeled rat GalR1,
GalR2 or GalR3 cDNA. Shown in Fig. 2 is a representative
blot of two independent Northern blot analyses. A band with
a strong signal atV2.4 kb was detected when hybridized with
radiolabeled rat GalR2 cDNA (Fig. 2, lane 2). The molecular
weight was similar to that of rat GalR2 transcripts found in
other tissues (V2^2.4 kb, [26,27,29]. In contrast, when the
hybridization was performed with the rat GalR1 or GalR3
cDNA as probe, a very faint band at the expected molecular
weight of 7^9 kb for GalR1, or of V4 kb for GalR3 mRNA
was observed (Fig. 2, lanes 1 and 3, respectively), indicating
that GalR1 and GalR3 were expressed at very low level in this
tissue. The faint bands seen at 2.4 kb on the blot arose from
cross-hybridization of the rat GalR1 and GalR3 cDNA
probes to the large amount of GalR2 transcript migrated at
this molecular weight (Fig. 2, lanes 1 and 3).
3.3. E¡ects of the galanin analogs on food intake in rats
Because of the well-established orexigenic activity of gala-
nin itself [16], we compared the activity of galanin(1^29), gal-
anin(1^16), galanin(2^29) and galanin(3^29) in a rat feeding
model. Galanin(1^29) potently stimulated food consumption
as evidenced by a dose-dependent increase in 1 h food intake
FEBS 20719 3-9-98
Table 1
Relative a⁄nities and potencies of galanin and galanin fragments in GalR1, GalR2 and GalR3 receptor binding, jejunal contraction and feed-
ing assays
Ligand Receptor Jejunum bioassay Feeding bioassay
GalR1 GalR2 GalR3
memba cellsb memb cells memb cells
Galanin(1^29) Ki (nM) 1.0 0.9 þ 0.1 1.5 5.6 þ 0.3 1.5 nd (V3.5)c 76 þ 26 +++++d
Ki/Kigal 1 1 1 1 1 1
Galanin(2^29) Ki (nM) 85 1100 þ 225 1.9 56 þ 5 12.6 nd (V264) 269 þ 57 þ
Ki/Kigal 85 1222 1.3 10 8.6 3.5
Galanin(1^16) Ki (nM) 4.8 6 þ 1 5.7 13 þ 2 50 nd (V88) 370 þ 195 þ
Ki/Kigal 4.8 6.6 3.9 2.3 34 4.8
Galanin Ki (nM) s 1000 s 2500 s 1000 s 3125 s 1000 nd (s 3125) s 10 000 3
Ki/Kigal s 1000 s 2778 s 650 s 558 s 650 s 132
In the radioligand binding assays, CHO cells were incubated with 0.3 nM [125I]porcine galanin in the presence of various concentrations of galanin
and its fragments (Fig. 4). Values are mean þ S.D. from two independent experiments performed in duplicate. Receptor a⁄nities of the peptides are
Ki (nM) calculated from EC50 values obtained by non-linear regression analysis of the binding data. Data of binding assays using membranes are
from [30]. In the jejunal contraction assays, jejunal contraction was measured in the presence of various concentrations of galanin and its fragments
and compared to that with 5 WM ACh. EC50 was determined from 5^8 measurements and represents mean þ S.E.M. (Fig. 1). Food intake by rats in
the feeding bioassay was measured after i.c.v. infusion of the peptide (Fig. 3.)
a‘memb’ indicates membrane binding assays.
b‘cells’ denotes the whole-cell binding assays. Ki/Kigal represents a⁄nity or potency of a ligand relative to that of galanin(1^29).
cValues in parentheses are estimated using the ratios of Kicell/Kimemb of GalR1 and GalR2 obtained with the same peptides. Note that the Kicell/
Kimemb ratio of each ligand is within 4-fold of variability, e.g. the Kicell/Kimemb values of galanin(1^29) are 0.9(0.9/1) for GalR1 and 37.5(5.6/1.5) for
GalR2, those of galanin(2^29) are 12.9(1100/85) for GalR1 and 29.4(56/1.9) for GalR2, and those of galanin(1^16) are 1.3(6/4.8) for GalR1 and
2.3(13/5.7) for GalR2.
dFeeding data are estimated based on the potencies of the peptides. +++++ denotes the highest e¡ect and 3 denotes no e¡ect (Fig. 3). nd, not
determined.
Fig. 2. Expression of rat GalR1, GalR2 and GalR3 in jejunum. 5 Wg
poly(A) RNA was loaded on each lane of an agarose gel and
after transfer of the RNA from the gel to Nylon ¢lter, the blot was
cut into three parts and then hybridized with 32P-labeled GalR1
(lane 1), GalR2 (lane 2) and GalR3 (lane 3) probes (labeled with a
random priming kit, BRL, speci¢c activity 2U109, 0.44U109 and
1U109 cpm/Wg for rat GalR1, GalR2 and GalR3 cDNA probes, re-
spectively). The hybridized blots were then washed and exposed to
a ¢lm identically. The blot was subsequently stripped and hybri-
dized with 32P-labeled L-actin cDNA (bottom panel). The numbers
on the left indicate standard molecular weights (kb).
Fig. 3. E¡ects of galanin and galanin fragments on food intake in
rats. Galanin peptides were infused i.c.v. into rats and food con-
sumption was monitored 1 h after the dosing. Values are presented
as mean þ S.E.M. (n = 6^24 animals/group). Statistical signi¢cance
between feeding responses to the galanin peptides was compared to
the saline vehicle treatment (1.31 þ 0.2 g food) by the paired Stu-
dent’s t-test. Symbols denote galanin(1^29) (b), galanin(1^16) (O),
galanin(2^29) (a) and galanin(3^29) (R).
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when infused i.c.v. at 1^10 nmol (Fig. 3). At all doses the
increase of food intake at 1 h was signi¢cantly higher than
that when saline was infused as control (P6 0.05, paired t-
test). In contrast, galanin(3^29) did not stimulate food intake
even at doses as high as 30 nmol, i.c.v. (Fig. 3). Galanin(2^29)
was also inactive in stimulation of food intake at 3 and 10
nmol. Only a small increase was observed when 30 nmol gal-
anin(2^29) was infused as compared to the animal’s saline
response (Fig. 3). Galanin(1^16) did not increase food intake
consistently over the three doses. The 10 nmol dose of gala-
nin(1^16) was signi¢cantly increased over the animals’ saline
infused baseline (P6 0.05, paired t-test), but the 30 nmol dose
was not signi¢cantly increased. These results demonstrate that
the galanin-stimulated food intake was mediated by a galanin
receptor that is activated by galanin(1^29), slightly activated
by galanin(1^16) and galanin(2^29), and incapable of being
activated by galanin(3^29).
3.4. E¡ects of galanin analogs in [125I]galanin binding assay
To correlate the results of jejunal contraction and food
intake with the pharmacological pro¢les of the de¢ned
GalR subtypes, we compared these results with pharmacolog-
ical pro¢les of the three cloned GalRs (Table 1) determined in
previous membrane binding assays [30] and binding assays
with intact CHO cells expressing GalR1 or GalR2 (Fig. 4).
In the whole-cell binding assays, galanin(1^29) competitively
inhibited the binding of [125I]galanin to both rat GalR1 and
GalR2 receptors with Ki values of 0.9 and 5.6 nM, respec-
tively, whereas galanin(3^29) did not displace the radioligand
from either GalR1 or GalR2 (Fig. 4). Galanin(1^16) bound
both GalR1 and GalR2 with high a⁄nity (Ki = 6^13 nM).
However, galanin(2^29) potently competed the radioligand
from GalR2 but not GalR1 (Ki of 1100 nM and 56 nM for
GalR1 and GalR2, respectively) (Fig. 4). Comparison of the
membrane and whole-cell binding data indicates that the two
types of assays produced consistent pro¢les for the GalRs
(Table 1). The pharmacological pro¢les of GalR1 and
GalR2 obtained with radioligand binding assays with whole-
cells (Fig. 4 and Table 1) and membranes (Table 1 and [30])
are consistent with those obtained with functional assays, such
as the inhibitory e¡ects of galanin and the fragments gala-
nin(2^29) and galanin(3^29) on forskolin-stimulated cAMP
production [33]. Although the low expression level of GalR3
in mammalian cells [30] did not allow generation of a CHO
cell line expressing enough GalR3 for the whole-cell binding
assay, the use of the GalR3 pharmacological pro¢le obtained
with membrane assay most likely represents the pro¢le of
GalR3 in the whole-cell assay (Table 1). Taken together, these
ligand binding studies have de¢ned distinct pharmacological
pro¢les for the three GalR subtypes: galanin(1^29) and gal-
anin(1^16) possess high and galanin(2^29) and galanin(3^39)
possess low relative binding a⁄nities (Kilig/Kigal) for GalR1
(Table 1). All the ligands, except galanin(3^29), possess high
a⁄nities for GalR2. For GalR3, the relative a⁄nities of gal-
anin(1^29) and galanin(2^29) are higher than those of gala-
nin(1^16) and galanin(3^29) (Table 1).
4. Discussion
Galanin is an unique gut-brain neuropeptide that regulates
a variety of physiological functions via activation of speci¢c G
protein-coupled receptors. Analysis of the structure-activity
relationship of galanin peptides with the three cloned GalR
subtypes demonstrated that the ligand binding is independent
of the C-terminus of galanin [20,26,30]. In other studies, a
putative galanin receptor that may require the C-terminus of
galanin has been suggested [8,18,36]. GalR1, GalR2 and
GalR3 may mediate di¡erent physiological functions because
the three cloned galanin receptors (1) are di¡erentially ex-
pressed among central and peripheral tissues; (2) activate dif-
ferent signal transduction pathways (Gi for GalR1, and Gq,
Go and Gi for GalR2); and (3) are pharmacologically distinct
[19,20,23,24,26^28,30]. The cloning of the three receptor sub-
types and identi¢cation of receptor subtype-selective ligands
galanin(2^29) and galanin(1^16) have enabled us to perform
experiments to directly di¡erentiate the roles of these receptor
subtypes in intestinal contraction and feeding paradigms (Ta-
ble 1). We have demonstrated that the two gut/brain functions
are mediated by di¡erent galanin receptors, as suggested by
earlier pharmacological studies [17].
Two lines of evidence support GalR2 as the galanin recep-
tor that mediates intestinal contraction. The pharmacological
pro¢le in jejunal contractions (Fig. 1 and Table 1), in which
high a⁄nity ligands galanin(1^29), galanin(2^29) and gala-
nin(1^16) are all active in stimulating jejunal contraction
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Fig. 4. Ligand binding pro¢les of cloned GalR1 and GalR2 recep-
tors. [125I]Porcine galanin at 0.3 nM was incubated with CHO cells
expressing GalR1 (A) or GalR2 (B) in the presence of rat gala-
nin(1^29) (b), galanin(1^16) (W), galanin(2^29) (a) and galanin(3^
29) (O). The data are expressed as percent of control (total binding
minus non-speci¢c binding). The total binding was 6354 þ 320 dpm
(n = 6) and 16 790 þ 1122 dpm (n = 6) for GalR1 and GalR2, respec-
tively; and the non-speci¢c binding, de¢ned by including 5 WM rat
galanin in the assays, was 647 þ 63 dpm (n = 4) and 2178 þ 163 dpm
(n = 4) for GalR1 and GalR2, respectively.
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whereas galanin(3^29) is ine¡ective, resembles only the phar-
macological pro¢le of the GalR2 galanin receptor (Fig. 4 and
Table 1). The ligand pro¢le of the contraction is markedly
di¡erent from those of GalR1 and GalR3, suggesting that
these GalRs do not play a role in this function. In addition,
abundant expression of GalR2 and minimum expression of
GalR1 and GalR3 detected in jejunum, as revealed by North-
ern blot analyses (Fig. 2), correlates with the observed phys-
iological activity of GalR2 (Fig. 1). The present ¢nding that
galanin(1^29), galanin(1^16) and galanin(2^29) are active but
galanin(3^29) is inactive in stimulation of the contraction is
consistent with previous results utilizing galanin fragments in
jejunal smooth muscle contraction models [37,38]. However,
in other studies, galanin(9^29) [8] and residues 25^29 of gal-
anin [18] were found to bind to jejunal membrane prepara-
tions. Binding of ligands to jejunal membranes may re£ect
binding to more than one receptor subtype, obscuring the
true pharmacological pro¢le of each receptor. Thus a ligand
such as galanin(3^29), although binding the membrane prep-
arations, may not activate the appropriate receptor subtype to
cause jejunal contraction. The approach taken in the present
study, in which jejunal contraction can be compared to the
pharmacological pro¢le of each individual receptor subtype
expressed in CHO and COS-7 cells (Table 1), allows a clearer
correlation to emerge. Human GalR1 receptor has been iso-
lated from mucosal cells lining the human gastrointestinal
tract by RT-PCR using human GalR1-speci¢c primers [21],
suggesting a role for galanin in regulation of intestinal epithe-
lial cell absorption [39]. In the present study, we extended to
measure the relative amounts of all the three GalR subtypes in
rat jejunum by Northern blot analysis. While the dominant
expression of GalR2 mRNA (Fig. 2) suggests a regulatory
role for this receptor in intestine, the detection of low levels
of GalR1 and GalR3 (Fig. 2) is consistent with the existence
of GalR1 in the mucosal cells, which can be readily ampli¢ed
by PCR using GalR1-speci¢c primers [21].
The second ¢nding in present study is that feeding behavior
is not mediated by either GalR2 or GalR3. GalR1 and GalR2
mRNAs have been found wildly distributed in rat brain by in
situ hybridization studies [23,28,32]. In these studies, the pat-
terns of the distributions were distinct but overlapping in sev-
eral regions of the brain, including hypothalamus and amyg-
dala, suggesting that one or both of the receptor subtypes may
mediate galanin-induced food intake. Chimeric galanin antag-
onists, M40 and C7, have been found to block galanin-in-
duced feeding in rats [40] but these ligands are generally not
GalR subtype-selective [30]. In the present study, we directly
employed feeding behavioral model and of GalR2/GalR3-se-
lective agonist galanin(2^29) (Fig. 2 and Table 1) to test the
possible roles of the three GalRs in feeding. The inability of
galanin(2^29) to stimulate food intake indicates that galanin-
stimulated food intake is mediated by a galanin receptor other
than GalR2 and GalR3 (Fig. 3 and Table 1).
The results obtained from the present study, however, can-
not de¢ne GalR1 as the feeding receptor because the low
activity of galanin(1^16) in the food intake assay (Fig. 3) is
not consistent with the high a⁄nity of the ligand for GalR1
(Table 1). Two possibilities exist to explain the data. (1) The
inactivity of galanin(1^16) may be resulted from endogenous
protease degradation. Galanin(1^16), lacking the C-terminal
13 amino acids of galanin, has been found to be markedly
more susceptible to proteolytic degradation in hypothalamus
membranes (t1=2 =V28 min) than galanin (t1=2 =V100 min)
[41]. Similarly, a higher degradation rate of galanin(1^16) in
cerebrospinal £uid, spinal cord membranes and plasma has
been observed [42,43]. It is therefore possible that the reduced
1 h food intake-stimulating activity of galanin(1^16) resulted
from i.c.v. degradation (Table 1). (2) An unidenti¢ed galanin
receptor (other than the three cloned GalRs [30] and the pu-
tative pituitary GalR [36]) that possesses a pharmacological
pro¢le matching that demonstrated in the feeding behavior of
rats (Fig. 3) may be responsible for mediating this function of
galanin. The putative pituitary galanin receptor, which re-
quires the C-terminus of galanin for high a⁄nity binding
[36], is unlikely to mediate either food intake or intestinal
contraction, since galanin(3^29), a ligand that binds to this
receptor with high a⁄nity and is active in stimulating prolac-
tin release [36], does not bind either GalR1, GalR2, or GalR3
(Table 1) and is inactive in both food intake and intestinal
contractions (Figs. 1 and 3).
In summary, we have studied roles of the three cloned gal-
anin receptors in two important central and peripheral func-
tions mediated by galanin. GalR2/GalR3-selective ligand gal-
anin(2^29) and GalR1/GalR2-selective ligand galanin(1^16)
were used in these studies to implicate the GalR2 galanin
receptor in the excitatory mechanism for small intestinal
smooth muscle contraction. In addition, our data suggest
that neither GalR2 nor GalR3 mediates galanin-stimulated
food intake. Positive identi¢cation of the ‘feeding receptor’
will require identi¢cation of potent GalR1-selective antago-
nists or generation of animals in which GalR1 is speci¢cally
disrupted by molecular approaches, and/or require isolation
of a new GalR subtype with an unique pharmacological pro-
¢le identical to that of the feeding behavior.
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